, showing 17α-OHP around the left-middle among the
pregnenes.
Biosynthesis 17α-OHP is derived from
progesterone via
17α-hydroxylase (encoded by
CYP17A1). 17α-OHP increases in the third trimester of
pregnancy primarily due to fetal adrenal production. This steroid is primarily produced in the
adrenal glands and to some degree in the
gonads, specifically the
corpus luteum of the
ovary. Normal levels are 3-90 ng/dl in children, and in women, 20-100 ng/dl prior to
ovulation, and 100-500 ng/dl during the
luteal phase.
Measurement Measurements of levels of 17α-OHP are useful in the evaluation of patients with suspected
congenital adrenal hyperplasia as the typical enzymes that are defective, namely
21-hydroxylase and
11β-hydroxylase, lead to a build-up of 17α-OHP. In contrast, the rare patient with
17α-hydroxylase deficiency will have very low or undetectable levels of 17α-OHP.
Immunoassays like RIA (
radioimmunoassay) or IRMA (immunoradiometric assay) used to clinically determine 17α-OHP are prone to cross-reactivity with the 17α-OHP steroid precursors and their sulphated conjugates.
Gas or
liquid chromatography and
mass spectrometry (e.g. LC-MS/MS) achieves greater specificity than immunoassays. Measurement of 17α-OHP by LC-MS/MS improves newborn screening for
congenital adrenal hyperplasia due to 21-hydroxylase deficiency, because 17α-OHP steroid precursors and their sulphated conjugates which are present in the first two days after birth and longer in pre-term neonates, cross-react in immunoassays with 17α-OHP, giving falsely high 17α-OHP levels. ==Pharmacology==